Calliditas Therapeutics AB (OSTO:CALTX, Financial) is set to release its Q3 2024 earnings on Nov 11, 2024. The consensus estimate for Q3 2024 revenue is $546.32 million, and the earnings are expected to come in at $1.08 per share. The full year 2024's revenue is expected to be $1.95 billion and the earnings are expected to be $0.78 per share. More detailed estimate data can be found on the Forecast page.
Calliditas Therapeutics AB (OSTO:CALTX, Financial) Estimates Trends
Over the past 90 days, revenue estimates for Calliditas Therapeutics AB (OSTO:CALTX) for the full year 2024 have increased from $1.87 billion to $1.95 billion, and for 2025, estimates have risen from $2.91 billion to $3.18 billion. Earnings estimates for the full year 2024 have increased from -$0.60 per share to $0.78 per share, and for 2025, from $13.45 per share to $18.64 per share.
Calliditas Therapeutics AB (OSTO:CALTX, Financial) Reported History
In the previous quarter of 2024-06-30, Calliditas Therapeutics AB's (OSTO:CALTX) actual revenue was $559.78 million, which beat analysts' revenue expectations of $445.35 million by 25.69%. Calliditas Therapeutics AB's (OSTO:CALTX) actual earnings were -$0.88 per share, which missed analysts' earnings expectations of -$0.30 per share by -190.43%. After releasing the results, Calliditas Therapeutics AB (OSTO:CALTX) was up by 0.1% in one day.
Calliditas Therapeutics AB (OSTO:CALTX, Financial) 12 Month Price Targets
Based on the one-year price targets offered by 4 analysts, the average target price for Calliditas Therapeutics AB (OSTO:CALTX) is $227.50 with a high estimate of $295 and a low estimate of $177. The average target implies an upside of 10.33% from the current price of $206.20.
Based on GuruFocus estimates, the estimated GF Value for Calliditas Therapeutics AB (OSTO:CALTX, Financial) in one year is $557.49, suggesting an upside of 170.36% from the current price of $206.20.
Based on the consensus recommendation from 5 brokerage firms, Calliditas Therapeutics AB's (OSTO:CALTX, Financial) average brokerage recommendation is currently 2.2, indicating an "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
